Early research (Phase 1)Study completedNCT03821233What this trial is testingA Dose Finding Study of ZW49 in Patients With HER2-Positive CancersWho this might be right forHER2-expressing Cancers Zymeworks BC Inc. 112
Large-scale testing (Phase 3)Looking for participantsNCT06901531What this trial is testingZolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerWho this might be right forLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more Astellas Pharma Global Development, Inc.
Not applicableAvailableNCT06048081What this trial is testingEarly Access Program for ZolbetuximabWho this might be right forLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507What this trial is testingZolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Who this might be right forLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04032704What this trial is testingLadiratuzumab Vedotin in Advanced Solid TumorsWho this might be right forSmall Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more Seagen Inc. 205
Early research (Phase 1)Looking for participantsNCT05365581What this trial is testingASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerWho this might be right forGastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma Astellas Pharma Global Development, Inc. 398
Not applicableLooking for participantsNCT06902545What this trial is testingObserve the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.Who this might be right forLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more Astellas Pharma Korea, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT06177041What this trial is testingM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.Who this might be right forLocally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Testing effectiveness (Phase 2)Study completedNCT03941873What this trial is testingInvestigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerWho this might be right forCarcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer BeiGene 111
Early research (Phase 1)Study completedNCT02443324What this trial is testingRamucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerWho this might be right forGastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more Eli Lilly and Company 175
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767What this trial is testingCombination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaWho this might be right forGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma Qilu Pharmaceutical Co., Ltd. 100
Early research (Phase 1)Study completedNCT02892123What this trial is testingTrial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersWho this might be right forHER2-expressing Cancers Jazz Pharmaceuticals 279
Early research (Phase 1)Active Not RecruitingNCT05539430What this trial is testingClaudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic AdenocarcinomaWho this might be right forGastric CancerGastroesophageal-junction CancerEsophageal Cancer+1 more Legend Biotech USA Inc 56
Large-scale testing (Phase 3)Study completedNCT04499924What this trial is testingTucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerWho this might be right forGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma Seagen Inc. 17
Large-scale testing (Phase 3)Active Not RecruitingNCT03504397What this trial is testingCompare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.Who this might be right forLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05702229What this trial is testingNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaWho this might be right forGastric Cancer AstraZeneca 240
Testing effectiveness (Phase 2)Ended earlyNCT05207722What this trial is testingCYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaWho this might be right forMetastatic HER2 Positive Gastroesophageal Junction Cancer Celularity Incorporated 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT03505320What this trial is testingZolbetuximab (IMAB362) in Adults With Gastric CancerWho this might be right forPharmacokinetics of ZolbetuximabGastric CancerGastro-esophageal Junction (GEJ) Cancer+2 more Astellas Pharma Global Development, Inc. 143
Testing effectiveness (Phase 2)Study completedNCT03281369What this trial is testingMultiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)Who this might be right forGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma Hoffmann-La Roche 214
Early research (Phase 1)Study completedNCT04086758What this trial is testingA Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaWho this might be right forGastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Astellas Pharma China, Inc. 12